Literature DB >> 2209616

Expression of argininosuccinate lyase mRNA in foetal hepatocytes. Regulation by glucocorticoids and insulin.

A Husson1, S Renouf, A Fairand, C Buquet, M Benamar, R Vaillant.   

Abstract

Argininosuccinate lyase (ASL), the fourth enzyme of the urea cycle, belongs to a group of liver enzymes appearing in the late foetal period in the rat. Several hormones, including glucocorticosteroids and insulin have been implicated in the control of the development of this enzyme activity. In this study, the cloned cDNA was used to measure the relative abundance of ASL mRNA in the livers of rats at various stages of perinatal development and in cultured foetal hepatocytes during hormonal manipulations. The ASL mRNA was first detectable on day 15.5 of gestation and increased in amount concomitantly with the rise in the enzyme activity, suggesting that the appearance of enzyme activity reflects the turning on of specific gene transcription. When foetal hepatocytes were exposed to dexamethasone, an increase in ASL mRNA was detected, which was completely abolished by addition of actinomycin D, suggesting a transcriptional effect of the steroid. In contrast, administration of cortisol to foetuses in utero had no effect on the mRNA level, suggesting that the steroid action is inhibited in the intra-uterine environment. Insulin might be the inhibiting factor since it completely repressed the dexamethasone-induced accumulation of ASL mRNA in foetal hepatocytes. These data were confirmed in vivo by experiments using streptozotocin, which produces insulin-depleted foetuses and causes the accumulation of ASL mRNA. This regulation of ASL mRNA by glucocorticoids and insulin could account for the modulation of the enzyme activity observed in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209616     DOI: 10.1111/j.1432-1033.1990.tb19275.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Effects of insulin on the regulation of branched-chain alpha-keto acid dehydrogenase E1 alpha subunit gene expression.

Authors:  P A Costeas; J M Chinsky
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

2.  AMP-activated protein kinase signaling regulated expression of urea cycle enzymes in response to changes in dietary protein intake.

Authors:  Sandra K Heibel; Peter J McGuire; Nantaporn Haskins; Himani D Majumdar; Sree Rayavarapu; Kanneboyina Nagaraju; Yetrib Hathout; Kristy Brown; Mendel Tuchman; Ljubica Caldovic
Journal:  J Inherit Metab Dis       Date:  2019-08-01       Impact factor: 4.982

Review 3.  Transcriptional regulation of genes for ornithine cycle enzymes.

Authors:  M Takiguchi; M Mori
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

4.  Insulin and glucocorticoid dependence of hepatic gamma-glutamylcysteine synthetase and glutathione synthesis in the rat. Studies in cultured hepatocytes and in vivo.

Authors:  S C Lu; J L Ge; J Kuhlenkamp; N Kaplowitz
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  Changes in levels of argininosuccinate lyase mRNA during induction by glucagon and cyclic AMP in cultured foetal-rat hepatocytes.

Authors:  S Renouf; C Buquet; A Fairand; M Benamar; A Husson
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

6.  Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes.

Authors:  R M O'Brien; E L Noisin; A Suwanichkul; T Yamasaki; P C Lucas; J C Wang; D R Powell; D K Granner
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

7.  Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria.

Authors:  Liyan Hu; Amit V Pandey; Sandra Eggimann; Véronique Rüfenacht; Dorothea Möslinger; Jean-Marc Nuoffer; Johannes Häberle
Journal:  J Biol Chem       Date:  2013-10-17       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.